No Significant Reduction of Circulating Endothelial-Derived and Platelet-Derived Microparticles in Patients with Psoriasis Successfully Treated with Anti-IL12/23.

Abstract

Psoriasis is associated with atherosclerosis, in which circulating microparticles play an important role. In severe psoriasis, there was an increase of endothelial- and platelet- microparticles which could be decreased by anti-TNFα. However, whether anti-IL-12/23 treatment would decrease the level of microparticles remains unknown. Our study showed that, despite the clinical improvement of psoriasis after IL-12/13 blockage, the increased levels of circulating CD41a and CD31 microparticles were unchanged after anti-IL-12/23. This result suggested that anti-IL12/23 treatment may not alter the development of cardiovascular disease in patients with psoriasis.

• Authors: Ji-Chen Ho, Chih-Hung Lee, Shang-Hung Lin
• Journal: BioMed research international (Biomed Res Int) Vol. 2016 Pg. 3242143 ( 2016) ISSN: 2314-6141 [Electronic] United States
• PMID: 27144162 (Publication Type: Clinical Trial, Journal Article)

Chemical References

• Interleukin-12 Subunit p40
• Ustekinumab

Topics

• Adult
• Aged
• Blood Platelets (drug effects, immunology, pathology)
• Cell-Derived Microparticles (drug effects, immunology, pathology)
• Endothelial Progenitor Cells (drug effects, immunology, pathology)
• Female
• Humans
• Interleukin-12 Subunit p40 (immunology)
• Male
• Middle Aged
• Psoriasis (blood, immunology, therapy)
• Treatment Outcome
• Ustekinumab (administration & dosage, immunology)